We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Newly diagnosed and previously treated multicentric Castleman disease respond equally to siltuximab.
- Authors
Rhee, Frits; Rossi, Jean‐François; Simpson, David; Fosså, Alexander; Dispenzieri, Angela; Kuruvilla, John; Goh, Yeow Tee; Cho, Seok‐Goo; Capra, Marcelo; Liu, Ting; Casper, Corey; Cavet, James; Wong, Raymond S.
- Abstract
Keywords: siltuximab; multicentric Castleman disease EN siltuximab multicentric Castleman disease e28 e31 4 12/21/20 20210101 NES 210101 Multicentric Castleman disease (MCD) is a lymphoproliferative disorder characterised by systemic symptoms, such as fatigue, fever, night sweats and weight loss, as well as multistation lymphadenopathy. In patients treated with siltuximab, the median TTF appeared to be longer for newly diagnosed patients compared with previously treated patients; however, a Cox interaction analysis showed there was no significant difference between treatment effect and prior treatment status ( I P i = 0-11). Prespecified subgroup analysis by treatment arm of the primary endpoint (durable tumour response by central review in the absence of symptom deterioration) in patients with previously treated or newly diagnosed multicentric Castleman disease. Number of subjects with treatment-emergent adverse events of any grade (occurring in >=10% of patients) or Grade >=3 (occurring in >=5% of patients).
- Subjects
INTERLEUKIN-6 receptors
- Publication
British Journal of Haematology, 2021, Vol 192, Issue 1, pe28
- ISSN
0007-1048
- Publication type
Article
- DOI
10.1111/bjh.17177